Table 2.
Baseline characteristics of the 70 kidney transplantation patients with or without metabolic syndrome
| Characteristic | No metabolic syndrome group (%) | Metabolic syndrome group (%) | P value | |
|---|---|---|---|---|
| Gender | Male | 29 (60.4) | 8 (36.4) | 0.061 |
| Female | 19 (39.6) | 14 (63.6) | ||
| Diabetes | No | 38 (79.2) | 9 (40.9) | 0.002* |
| Yes | 10 (20.8) | 13 (59.1) | ||
| Hypertension | No | 31 (64.6) | 7 (31.8) | 0.011* |
| Yes | 17 (35.4) | 15 (68.2) | ||
| Transplantation model | Cadaveric | 42 (87.5) | 19 (86.4) | 0.895 |
| Living | 6 (12.5) | 3 (13.6) | ||
| Tacrolimus use | No | 18 (37.5) | 11 (50.0) | 0.324 |
| Yes | 30 (62.5) | 11 (50.0) | ||
| Mycophenolate mofetil or mycophenolic acid use | No | 13 (27.1) | 8 (36.4) | 0.432 |
| Yes | 35 (72.9) | 14 (63.6) | ||
| Steroid use | No | 11 (22.9) | 2 (9.1) | 0.167 |
| Yes | 37 (77.1) | 20 (90.9) | ||
| Rapamycin use | No | 39 (81.2) | 17 (77.3) | 0.699 |
| Yes | 9 (18.8) | 5 (22.7) | ||
| Cyclosporine use | No | 39 (81.2) | 15 (68.2) | 0.227 |
| Yes | 9 (18.8) | 7 (31.8) | ||
*
P < 0.05 was considered statistically significant.
Data are expressed as number of patients, and analysis was carried out using the chi-square test.